These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26342469)

  • 1. Value of the SYNTAX score for periprocedural myocardial infarction according to WHO and the third universal definition of myocardial infarction: insights from the TWENTE trial.
    Tandjung K; Lam MK; Sen H; de Man FH; Louwerenburg JH; Stoel MG; van Houwelingen KG; Linssen GC; van der Palen J; Doggen CJ; von Birgelen C
    EuroIntervention; 2016 Jul; 12(4):431-40. PubMed ID: 26342469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of periprocedural myocardial infarction following stent implantation: comparison between first- and second-generation drug-eluting stents.
    Tandjung K; Basalus MW; Muurman E; Louwerenburg HW; van Houwelingen KG; Stoel MG; de Man FH; Jansen H; Huisman J; Linssen GC; Droste HT; Nienhuis MB; von Birgelen C
    Catheter Cardiovasc Interv; 2012 Oct; 80(4):524-30. PubMed ID: 22109857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.
    Garg S; Serruys PW; Silber S; Wykrzykowska J; van Geuns RJ; Richardt G; Buszman PE; Kelbæk H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; DiMario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli A; Van Remortel E; Ronden J; Windecker S
    JACC Cardiovasc Interv; 2011 Apr; 4(4):432-41. PubMed ID: 21511223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness and Safety of New-Generation Versus Early-Generation Drug-Eluting Stents According to Complexity of Coronary Artery Disease: A Patient-Level Pooled Analysis of 6,081 Patients.
    Piccolo R; Pilgrim T; Heg D; Franzone A; Rat-Wirtzler J; Räber L; Silber S; Serruys PW; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2015 Nov; 8(13):1657-66. PubMed ID: 26585615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk stratification of periprocedural myocardial infarction after percutaneous coronary intervention: Analysis based on the SCAI definition.
    Zhang D; Li Y; Yin D; He Y; Chen C; Song C; Yan R; Zhu C; Xu B; Dou K
    Catheter Cardiovasc Interv; 2017 Mar; 89(S1):534-540. PubMed ID: 28191726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trial.
    Lam MK; Tandjung K; Sen H; Basalus MW; van Houwelingen KG; Stoel MG; Louwerenburg JW; Linssen GC; Saïd SA; Nienhuis MB; de Man FH; van der Palen J; von Birgelen C
    EuroIntervention; 2015 Jun; 11(2):180-7. PubMed ID: 24602919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
    JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Periprocedural myocardial infarction is associated with increased mortality in patients with coronary artery bifurcation lesions after implantation of a drug-eluting stent.
    Chen SL; Zhang JJ; Ye F; Tian NL; Sheiban I; Jepson N; Paiboon C; Sansoto T; Kwan TW; Wen SY; Wang HC; Jiang TM; Wang Y; Chen LL; Qiu CG; Zhang YJ; Chen MX; De Maria A
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():696-705. PubMed ID: 25631678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Varying definitions for periprocedural myocardial infarction alter event rates and prognostic implications.
    Idris H; Lo S; Shugman IM; Saad Y; Hopkins AP; Mussap C; Leung D; Thomas L; Juergens CP; French JK
    J Am Heart Assoc; 2014 Oct; 3(6):e001086. PubMed ID: 25359403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Strut Width in Periprocedural Myocardial Infarction: A Propensity-Matched Comparison Between Bioresorbable Scaffolds and the First-Generation Sirolimus-Eluting Stent.
    Kawamoto H; Panoulas VF; Sato K; Miyazaki T; Naganuma T; Sticchi A; Figini F; Latib A; Chieffo A; Carlino M; Montorfano M; Colombo A
    JACC Cardiovasc Interv; 2015 Jun; 8(7):900-9. PubMed ID: 26003020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anatomic- and clinical-based NERS (new risk stratification) score II to predict clinical outcomes after stenting unprotected left main coronary artery disease: results from a multicenter, prospective, registry study.
    Chen SL; Han YL; Zhang YJ; Ye F; Liu HW; Zhang JJ; Xu B; Jiang TM; Zhou YJ; Lv SZ
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1233-41. PubMed ID: 24239199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients.
    Koskinas KC; Siontis GC; Piccolo R; Franzone A; Haynes A; Rat-Wirtzler J; Silber S; Serruys PW; Pilgrim T; Räber L; Heg D; Jüni P; Windecker S
    Circ Cardiovasc Interv; 2016 Feb; 9(2):e003255. PubMed ID: 26823484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry.
    Lindsey JB; Marso SP; Pencina M; Stolker JM; Kennedy KF; Rihal C; Barsness G; Piana RN; Goldberg SL; Cutlip DE; Kleiman NS; Cohen DJ;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1074-82. PubMed ID: 19926047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.
    Ishibashi Y; Muramatsu T; Nakatani S; Sotomi Y; Suwannasom P; Grundeken MJ; Cho YK; Garcia-Garcia HM; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; McClean D; de Sousa Almeida M; Wasungu L; Miquel-Hebert K; Dudek D; Chevalier B; Onuma Y; Serruys PW
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1053-1063. PubMed ID: 26205444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
    Zhang Q; Wang XL; Liao ML; Hu J; Yang ZK; Ding FH; Zhang JS; Du R; Zhu TQ; Shen WF; Zhang RY
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():762-9. PubMed ID: 25630513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of peri-procedural myocardial infarction with mortality after stenting true coronary bifurcation lesions: A pooled individual participant data analysis from four randomized controlled trials.
    Sheiban I; Ge Z; Kan J; Nie S; Zhang JJ; Santoso T; Munawar M; Ye F; Han Y; Chen SL;
    Catheter Cardiovasc Interv; 2022 Feb; 99(3):617-626. PubMed ID: 34494355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions.
    Pervaiz MH; Sood P; Sudhir K; Hermiller JB; Hou L; Hattori K; Su X; Cao S; Wang J; Applegate RJ; Kereiakes DJ; Yaqub M; Stone GW; Cutlip DE
    Circ Cardiovasc Interv; 2012 Apr; 5(2):150-6. PubMed ID: 22438430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.
    van der Heijden LC; Kok MM; Lam MK; Danse PW; Schramm AR; Jessurun GA; Tjon Joe Gin RM; van Houwelingen KG; Hautvast RW; Linssen GC; Sen H; Löwik MM; IJzerman MJ; Doggen CJ; von Birgelen C
    Clin Res Cardiol; 2016 Mar; 105(3):206-15. PubMed ID: 26329584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SYNTAX score and the risk of stent thrombosis after percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: an ACUITY trial substudy.
    Yadav M; Généreux P; Palmerini T; Caixeta A; Madhavan MV; Xu K; Brener SJ; Mehran R; Stone GW
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):1-10. PubMed ID: 24408084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.